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Abstract 
Circadian rhythms refer to the endogenous rhythms that are generated to synchronize physiology and behavior with 
24-h environmental cues. These rhythms are regulated by both external cues and molecular clock mechanisms in 
almost all cells. Disruption of circadian rhythms, which is called circadian disruption, affects many biological processes 
within the body and results in different long-term diseases, including cancer. Circadian regulatory pathways result in 
rhythmic epigenetic modifications and the formation of circadian epigenomes. Aberrant epigenetic modifications, 
such as hypermethylation, due to circadian disruption may be involved in the transformation of normal cells into 
cancer cells. Several studies have indicated an epigenetic basis for the carcinogenic effects of circadian disruption. In 
this review, I first discuss some of the circadian genes and regulatory proteins. Then, I summarize the current evidence 
related to the epigenetic modifications that result in circadian disruption. In addition, I explain the carcinogenic 
effects of circadian disruption and highlight its potential role in different human cancers using an epigenetic view-
point. Finally, the importance of chronotherapy in cancer treatment is highlighted.
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Introduction
The circadian timing system consists of a master clock 
that is located in the suprachiasmatic nucleus (SCN) of 
the hypothalamus. There are also many subsidiary clocks 
that are located in other parts of the brain, peripheral tis-
sues, and body cells [1, 2]. Circadian clocks refer to the 
circadian timing system, which generates and orches-
trates circadian rhythms. Circadian rhythms, which 
occur in most living organisms, are endogenous rhythms 
that are generated to synchronize physiology and behav-
ior with 24-h environmental cues [1, 3, 4]. Circadian 
rhythms are involved in many tissue-specific processes 
ranging from gene expression to behavior. In fact, circa-
dian rhythms are regulated not only by external cues but 
also by molecular clock mechanisms within almost all 
cells [5]. These molecular clocks are driven by interlocked 
transcriptional-translational feedback loops and inte-
grated with various metabolic and environmental cues [4, 
6].
Molecular circadian clocks govern the daily expression 
of thousands of tissue-specific genes [7]. Disharmony 
between these circadian clocks and environmental cues 
is referred to as circadian disruption. The human lifestyle 
and the entrainment of circadian rhythms have changed 
radically during the last two centuries [8]. In addition, 
the advent of electric lights and the movement from a 
traditional to a modern lifestyle have led to exposure 
to artificial light and other circadian misalignments [9]. 
Circadian disruption leads to the occurrence of various 
long-term diseases, including cancer [1, 10, 11].
Several environmental factors, such as night-shift work, 
exposure to artificial light, irregular diet, and electro-
magnetic (EM) waves, which affect biological processes 
mostly by altering melatonin rhythms, result in circadian 
disruption [12]. Because light is the most potent syn-
chronizer of circadian rhythms to the external environ-
ment, night-shift work and exposure to artificial light are 
the strongest disruptive factors of circadian rhythms [9]. 
The majority of shift workers in the industrialized world 
suffer from forced night-shift work and its harmful con-
sequences [8]. Möller-Levet et al. [13], through transcrip-
tome analysis, revealed that insufficient sleep can lead 
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to the up- or down-regulation of 711 genes. They also 
reported that insufficient sleep can reduce the number of 
genes with a circadian expression pattern. Furthermore, 
they reported that several circadian genes, such as the 
PER (Period) family genes, circadian locomotor output 
cycles kaput (CLOCK) and cryptochrome circadian clock 
2 (CRY2), can be affected by insufficient sleep [13].
Reviews
Circadian genes and regulatory proteins
The circadian timing system includes two interconnected 
molecular loops that involve at least nine genes [14]. In 
mammals, brain and muscle ARNT-like 1 (BMAL1) and 
CLOCK are the two master genes involved in the regula-
tion of circadian gene expression and biological functions 
[15]. In one of the loops (core loop), the two transcrip-
tion factors BMAL1 and CLOCK form a complex that 
binds to specific regions of DNA called enhancer-boxes 
(E-boxes). A highly conserved intermolecular zinc fin-
ger is integrated into this complex for further stabiliza-
tion. The CLOCK:BMAL1 complex binds to E-boxes of 
some of its target genes, such as CRY1, CRY2, PER1, and 
PER2, to increase their expression levels. In contrast, the 
protein products of these genes oppose the activity of the 
CLOCK:BMAL1 complex and consequently form a nega-
tive feedback loop that suppresses their own expression 
[2, 6]. In the other loop (secondary loop), BMAL1 also 
acts as a transcriptional regulator in collaboration with 
CLOCK. The CLOCK:BMAL1 complex binds to the pro-
moter-localized E-boxes of two genes, nuclear receptor 
subfamily 1 group D member 1 (NR1D1) and RAR-related 
orphan receptor A (RORA), and activates their transcrip-
tion. The genes NR1D1 and RORA code for two nuclear 
receptors, nuclear receptor subfamily 1 group D mem-
ber 1 (REV-ERBα) and RORα, respectively. The proteins 
REV-ERBα and RORα function as transcription factors. 
These nuclear receptors have a shared DNA-binding ele-
ment called RORE within the BMAL1 promoter, and they 
compete with each other to bind to RORE. REV-ERBα 
represses BMAL1 and CLOCK expression, whereas RORα 
activates the transcription of BMAL1. Hence, the cyclic 
production of these two nuclear receptors results in the 
cyclic expression of CLOCK and BMAL1 [16, 17] (Fig. 1).
Circadian epigenetic modifications
The clock machinery, a synchronized system of transcrip-
tion and translation, is responsible for creating the circa-
dian epigenome. The circadian epigenome refers to the 
epigenetic content of the genome that is formed through 
different circadian regulatory pathways. These regulatory 
pathways involve reversible changes in chromatin transi-
tions and epigenetic content [3, 18]. Several components 
are involved in these regulatory pathways. For example, 
deacetylase silent information regulation 2 homolog 1 
(SIRT1) is a key factor in circadian control that reflects 
environmental changes [19]. The enzyme SIRT1 represses 
circadian gene expression and also rhythmically reduces 
histone H3 K9/K14 acetylation at related DNA promot-
ers. In fact, SIRT1 is an NAD(+)-dependent deacetylase. 
The quantity of coenzyme NAD(+) follows circadian 
fluctuations, which results in the regulation of SIRT1 in a 
circadian manner [20]. In addition, several circadian epi-
genetic modifiers function in a tissue-specific manner. For 
example, in the liver, a histone methyltransferase called 
mixed lineage leukemia 3 (MLL3) both directly and indi-
rectly controls more than a hundred circadian “output” 
genes that are epigenetically targeted [7].
The clock machinery controls transcription through-
out the genome and is a critical factor in the temporal 
programming of tissue physiology [7]. Rhythmic recruit-
ment of key factors that modify chromatin structure and 
transcriptional and translational processes leads to the 
circadian organization of the mammalian transcriptome. 
Archer et  al. [21] analyzed the human blood transcrip-
tome and found that the forced desynchronization of 
sleep reduced rhythmic transcripts from 6.4% to 1.0%. 
The reduced transcripts were those involving regulation 
of transcription and translation, especially transcription 
of core clock genes [21]. Furthermore, Haus et  al. [22] 
reported that DNA in human peripheral blood cells is 
methylated in a circadian manner.
Clock proteins are involved in the coordination of dif-
ferent processes, such as covalent modifications, nuclear 
import/export, and proteolytic degradation. Epigenetic 
modification is a significant factor required for the proper 
function of these proteins. In addition, epigenetic modi-
fications such as histone methylation, acetylation, and 
phosphorylation regulate the circadian rhythm of the 
expression of the genes that encode these proteins. Chro-
matin remodeling has been previously reported as an 
important factor that regulates the expression of both key 
clock components and clock-controlled genes (CCGs). 
Several environmental factors affect chromatin remod-
eling. For instance, light pulses stimulate the rapid phos-
phorylation of histone H3 at serine 10 in SCN [10]. Azzi 
et al. [23] showed that temporarily exposing mice to light 
can strikingly alter the overall expression of circadian 
genes in SCN. They also revealed, by genome-wide meth-
ylation profiling, that such external changes affect the 
methylation pattern of promoter DNA in SCN. To further 
prove this issue, they showed that interference by a meth-
yltransferase inhibitor in SCN can suppress these period 
and epigenetic changes. They also reported that pro-
longed re-entrainment to a 24-h period can reverse these 
epigenetic modifications, supporting the presence of flex-
ibility in SCN to coordinate with external changes [23].
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Clock proteins are also involved in several epigenetic 
modifications. For example, CLOCK has intrinsic histone 
acetyl transferase (HAT) activity, and BMAL1, as the part-
ner of CLOCK, enhances its HAT function [24]. Further-
more, CLOCK and BMAL1 both acetylate non-histone 
proteins and are involved in various metabolic pathways 
that affect the cell cycle [10]. Due to the important roles 
of these proteins in the regulation of the cell cycle, down-
regulation of them may lead to tumorigenesis and malig-
nancy. For example, transcriptionally silencing BMAL1 
by hypermethylating its promoter results in the reduced 
formation of CLOCK:BMAL1 complex and consequently 
promotes malignancy [25]. Additionally, rhythmic binding 
of the CLOCK:BMAL1 complex to DNA results in rhyth-
mic chromatin modification, which mediates the rhyth-
mic binding of other nearby transcription factors [15]. In 
contrast, the histone deacetylase SIRT1 associates with the 
CLOCK:BMAL1 complex and antagonistically deacetylates 
various non-histone proteins, including BMAL1. In addition, 
the formation of the CLOCK:BMAL1:SIRT1 complex results 
in the induction of a large amount of gene transcription, 
including many CCGs that contain an E-box within their 
promoter [26]. Moreover, other epigenetic marks are also 
involved in circadian transcriptional/translational regula-
tion. The activation mark histone H3, when trimethylated at 
lysine 4 (H3K4me3), has a circadian pattern at thousands of 
genomic loci [7]. Together, the available literature indicates 
that many proteins are involved in the synchronization of 
circadian rhythms by exerting epigenetic modifications [27].
Circadian disruption and carcinogenesis
Circadian disruption has been implicated in the develop-
ment of different human cancers (Table  1). Disruption 
of circadian rhythms leads to epigenetic modifications, 
which may alter cell proliferation and subsequently result 
in oncogenesis and cancer [22] (Fig.  2). For example, 
Fig. 1 Two major interconnected molecular loops in the circadian machinery. The circadian machinery includes two interconnected molecular 
loops. In both of these loops, circadian locomotor output cycles kaput (CLOCK) and brain and muscle ARNT-like 1 (BMAL1) are the key players, and 
they form a dimer complex. In the core loop, the CLOCK:BMAL1 complex binds to enhancer-boxes (E-boxes) of some of its target genes, including 
cryptochrome circadian clock 1 (CRY1), CRY2, period circadian clock 1 (PER1), and PER2, and activates their expression. When the amount of CRY 
and PER proteins reaches a critical level, they suppress the activity of the CLOCK:BMAL1 complex. In this way, they suppress their own expression 
by forming a negative feedback loop. In the secondary loop, the CLOCK:BMAL1 complex binds to E-boxes in two genes, nuclear receptor subfam-
ily 1 group D member 1 (NR1D1) and RAR-related orphan receptor A (RORA), and activates their expression. The genes NR1D1 and RORA code for 
two nuclear receptors, nuclear receptor subfamily 1 group D member 1 (REV-ERBα) and RORα, respectively. These two nuclear receptors compete 
with each other to bind to a shared DNA-binding element called RORE within the BMAL1 promoter. RORα activates the transcription of BMAL1, 
while REV-ERBα represses BMAL1 expression. These two molecular loops impact each other by affecting the activity and expression of BMAL1 in a 
circadian fashion.
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Table 1 Disruption of circadian gene expression in different cancers
NPAS2 neuronal PAS domain protein 2, CLOCK circadian locomotor output cycles kaput, CRY2 cryptochrome circadian clock 2, TIMELESS timeless circadian clock, 
PER1/2/3 period circadian clock 1/2/3, CRY1/2 cryptochrome circadian clock 1/2, BMAL1 brain and muscle ARNT-like 1, CKIε casein kinase I isoform epsilon, Wee1 
WEE1 G2 checkpoint kinase, Cyclin D1 parathyroid adenomatosis 1, Myc v-myc myelocytomatosis viral oncogene homolog, TIM transforming immortalized mammary 
oncogene.
Cancer type Involved gene(s) Reference(s)
Breast cancer NPAS2, CLOCK, CRY2, TIMELESS, PER1, PER2, CRY1, and BMAL1 [12, 40]
Chronic myeloid leukemia (CML) CRY1, CRY2, PER1, PER2, PER3, CKIε, and BMAL1 [12, 43, 58]
Chronic lymphocytic leukemia (CLL) PER1, PER2, BMAL1, Wee1, Cyclin D1, and Myc [30]
Ovarian cancer BMAL1 [44]
Colorectal cancer (CRC) BMAL1 [47]
Prostate cancer PER1, PER2, PER3, CKIε, CRY1, CRY2, BMAL1, CLOCK, and NPAS2 [59, 60]
Non–small cell lung cancer (NSCLC) PER1 [51]
Gastric cancer PER2 and CRY1 [29]
Head and neck squamous cell carcinoma (HNSCC) PER1, PER2, PER3, CRY1, CRY2, CKIε, BMAL1, and TIM [61]
Fig. 2 Different circadian disruptive factors that lead to cancer. Circadian rhythms are disrupted in a variety of ways. Several environmental factors, 
such as night-shift work, exposure to artificial light, and exposure to electromagnetic (EM) waves, result in circadian disruption mostly by altering 
melatonin rhythms. Irregular diet may also lead to circadian disruption. Moreover, impaired circadian gene expression, due to mutation or epige-
netic factors, also results in circadian disruption. Disrupted circadian rhythms both directly and indirectly lead to aberrant epigenetic modifications 
that result in cell proliferation and cancer.
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disruption of melatonin rhythms is related to carcino-
genesis. Many of these circadian disruptions are due to 
dramatic changes resulting from industrialization and 
the development of societies and consequent changes 
in lifestyle over the past few hundred years [12]. Epige-
netic changes can be the result of several environmental 
factors, including repeated circadian disruption due to 
long-term shift work. Studies on shift workers have dem-
onstrated changes in the DNA methylation of their genes 
[22]. It has been reported that 15%–20% of workers have 
shift work schedules worldwide. In 2007, the Interna-
tional Agency for Research on Cancer (IARC) reported 
that shift work may be a carcinogenic factor in humans 
[28]. In addition, studies of breast cancer in women with 
shift work schedules have provided more evidence for the 
carcinogenic effects of circadian disruption [29].
The synchronization of circadian rhythms results not 
only from the regulation of core clock genes but also 
from the regulation of various clock-controlled genes, 
including several cell cycle genes [30]. The clock machin-
ery and cell cycle are controlled by similar mechanisms 
that include feedback loops. It has also been reported 
that the clock machinery has functional interactions with 
cell cycle regulators, so that changes in clock function 
result in uncontrolled cell cycle progression and cell pro-
liferation [31]. Furthermore, due to associations between 
the circadian clock and cell metabolism, circadian dis-
ruption results in abnormal cell metabolism. All of these 
abnormalities are important factors in the process of car-
cinogenesis and can result in multi-tumorigenesis [32, 
33]. The association between the cell cycle and the circa-
dian clock indicates that regulation of circadian rhythms 
can control the cell cycle; however, regulation of the cell 
cycle at various checkpoints can also influence biological 
rhythms [34].
Dysfunction of the clock machinery and cellular oscil-
lators is involved in tumorigenesis. Disruption of the 
expression of clock genes has also been observed in can-
cer patients [35]. For example, the core clock genes PER1 
and PER2 are known tumor suppressor genes, and their 
knockdown results in the doubling of tumor number 
and cancer growth; in contrast, overexpression of these 
genes decreases tumor number and cancer growth [36]. 
In addition, transcriptional silencing of the BMAL1 gene 
through hypermethylation of its promoter CpG island 
has been observed in hematologic malignancies [25]. Dis-
ruption of circadian rhythms results in the up- or down-
regulation of several genes and proteins, which when 
combined lead to carcinogenesis. Long interspersed 
element-1 (L1) is a protein complex that promotes 
genomic instability through DNA double-strand breaks 
and insertional mutagenesis. Up-regulation of L1 has 
been reported in many human malignancies. Melatonin 
receptor 1 acts as an inhibitor of L1 mobilization by 
down-regulating L1 mRNA and the open reading frame 
1 (ORF1) protein. Hence, exposure to environmental 
light regulates the expression of L1 through the regula-
tion of melatonin production. This association indicates 
that suppression of melatonin production due to forced 
exposure to light increases L1-induced genomic instabil-
ity and consequently promotes carcinogenesis [37]. Fur-
thermore, it has been shown that some long non-coding 
RNAs (lncRNAs) directly and indirectly alter melatonin 
synthesis. It has also been shown that the abundance of 
these lncRNAs changes in a circadian manner. These 
findings altogether indicate that circadian disruption may 
also alter melatonin expression and consequently pro-
mote carcinogenesis by changing the abundance of cer-
tain lncRNAs [38].
Breast cancer
Epigenetic modifications play an important role in 
increasing susceptibility to breast cancer. In addition, 
epigenetic aberrations resulting from disruption of envi-
ronmental factors (e.g., day-night cycles) may promote 
the development of breast cancer [39]. Clock genes are 
associated with various functions that are relevant to 
carcinogenesis. Variants of some circadian genes, such 
as neuronal PAS domain protein 2 (NPAS2), circadian 
locomotor output cycles kaput (CLOCK), cryptochrome 
circadian clock 2 (CRY2), and timeless circadian clock 
(TIMELESS), have been reported to be associated with 
breast cancer risk [40]. It has also been shown that expo-
sure to light at night markedly increases the growth of 
human breast cancer xenografts in rats [41]. Exposure to 
light at night also reduces melatonin levels and may con-
sequently result in increased estrogen production and 
altered estrogen receptor function. These results together 
lead to increased breast cancer risk [42]. Shanmugam 
et al. [12] reported the existence of hypermethylation on 
the promoters of PER1, PER2, CRY1, and BMAL1 in 37 of 
53 breast cancer cell lines. This observation provides evi-
dence for the underlying epigenetic mechanisms of clock 
gene deregulation and its carcinogenic effects [12].
Leukemia
The association between disruption of circadian rhythms 
and genes and some types of leukemia has been reported. 
It has been demonstrated that the expression levels of 
the human CRY1, CRY2, PER1, PER2, PER3, and BMAL1 
genes were down-regulated in both the chronic phase 
and blast crisis in chronic myeloid leukemia (CML) 
[43]. In addition, methylation analysis showed that CpG 
islands of the human PER3 gene were methylated in all of 
the CML patients, indicating an epigenetic basis for clock 
gene deregulation [12, 43].
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Rana et al. [30] investigated the expression of four cir-
cadian clock genes (PER1, PER2, BMAL1, and CLOCK) 
and three clock-controlled cell cycle genes (Wee1, Cyclin 
D1, and Myc) in 37 patients with chronic lymphocytic 
leukemia (CLL) and an equal number of healthy controls. 
They also measured serum melatonin levels in peripheral 
blood to investigate circadian disruption. Their results 
revealed the down-regulation of PER1, PER2, BMAL1, 
and Wee1 genes and the up-regulation of Cyclin D1 and 
Myc genes in CLL patients, compared with healthy con-
trols. They reported that the aberrant expression of cir-
cadian clock genes can result in the aberrant expression 
of downstream target genes that are associated with cell 
proliferation and apoptosis, which consequently may lead 
to CLL [30].
Ovarian cancer
Ovarian cancer is known as the fifth leading cause of 
cancer death in women worldwide [44]. In a study of a 
sample population of American women over 28  years, 
the association between circadian disruption and the 
risk of fatal ovarian cancer was investigated [45]. In 
this study, three types of circadian disruption including 
rotating work schedule, monthly frequency of insom-
nia, and nightly sleep duration were measured. During 
the follow-up time, 1,289 deaths occurred from ovarian 
cancer in the at-risk cohort. Finally, this study indicated 
that elevated risk of fatal ovarian cancer has an important 
association with a rotating work schedule, but it has no 
significant association with sleep duration or insomnia.
Development of ovarian cancer can be promoted by 
epigenetic modifications. Aberrant hypermethylation of 
the promoters of certain genes is an important hallmark 
of cancer cells. Yeh et al. [44] analyzed the CpG islands 
of genes in various ovarian cancer cell lines and demon-
strated that BMAL1, a core clock gene, is methylated in a 
subset of ovarian cancer cell lines. Specifically, the pro-
moter of BMAL1 is trimethylated on histone H3 at lysine 
27 by enhancer of Zeste homolog 2 (EZH2) in ovarian 
cancer CP70 and MCP2 cells. The authors showed that 
treatment of these cells with GSK126, an inhibitor of 
EZH2, can restore BMAL1 expression. Furthermore, 
overexpression of BMAL1 inhibits cell growth, enhances 
chemosensitivity to cisplatin, and restores the rhythmic 
activity of c-MYC in ovarian cancer cells. Finally, they 
presented BMAL1 as a tumor suppressor gene that is epi-
genetically silenced in ovarian cancer cells [44].
Colorectal cancer (CRC)
Disruption by circadian environmental cues occurs 
due to several factors, such as rotating shift work, and 
is involved in tumorigenesis and known to be a carci-
nogenic factor. It has been reported that disruption of 
circadian rhythms in shift workers is associated with 
an increased incidence of colorectal neoplastic disease 
[35]. Considering that the regulation of digestion occurs 
according to a circadian clock machinery, circadian dis-
ruptive factors such as dietary deficiencies may impair 
this regulation and influence carcinogen metabolism, 
thereby contributing to CRC [46]. Zeng et al. [47] inves-
tigated the association between BMAL1 expression level 
and CRC cell proliferation using three CRC cell lines, 
HCT116, HT29, and THC8307. They reported that 
BMAL1 overexpression inhibited CRC cell proliferation 
and also increased CRC sensitivity to oxaliplatin in vitro 
and in vivo. Moreover, CRC patients with a high BMAL1 
expression level had longer overall survival and progres-
sion-free survival compared with those who had a low 
BMAL1 expression level. Specifically, BMAL1 exerts its 
effects on the regulation of G2/M arrest by activating the 
ATM pathway [47].
Prostate cancer
Short sleep duration, insomnia, and shift work schedules 
are some of the factors that disrupt circadian rhythms. 
The Cancer Prevention Study–II group performed a pro-
spective study on men who experienced these circadian 
disruptive factors [29]. They reported that there was an 
association between short sleep duration and high risk of 
fatal prostate cancer only during the first 8 years of fol-
low-up. This association suggests that short sleep dura-
tion can affect later clinical stages of prostate cancer. In 
another study on 2,102 men, Sigurdardottir et  al. [48] 
investigated the association between sleep disruption 
and the risk of prostate cancer. In this study, 6.4% of men 
were diagnosed with prostate cancer during the follow-
up time. They suggested that certain aspects of sleep dis-
ruption may increase the risk of prostate cancer [48].
Lung cancer
Disruption of circadian rhythms in lung function has 
been observed in patients with obstructive lung disease. 
Environmental tobacco/cigarette smoke (CS) can also 
alter the expression of BMAL1 through Sirtuin1 (SIRT1) 
deacetylase [49]. In a study that aimed at determining the 
association between circadian disruption and quality of 
life among patients with advanced lung cancer, Grutsch 
et  al. [50] investigated this association in 84 patients 
and found that behavioral, hormonal, and/or light-
based strategies may improve circadian organization 
and help advanced lung cancer patients to experience 
better feeling and function. Another study on the epige-
netic basis of non–small cell lung cancer (NSCLC) used 
microarray analysis to focus on tumor suppressor genes 
silenced by DNA methylation and histone deacetylation. 
In this study, PER1 was presented as a candidate tumor 
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suppressor in lung cancer. It was also revealed that PER1 
expression levels were significantly higher in normal lung 
samples compared with NSCLC patient samples and cell 
lines. In addition, forced PER1 expression in NSCLC cell 
lines resulted in marked reductions in growth and the 
loss of clonogenic survival. These results indicated that 
circadian disruption plays an important role in lung tum-
origenesis [51]. Furthermore, the association between 
impairment of BMAL1 expression and disruption of cir-
cadian rhythms in lung function suggests that circadian 
disruption may be involved in lung cancer through alter-
ations of BMAL1 expression.
Gastric cancer
Gapstur et  al. [29] investigated the expression of eight 
circadian clock genes including PER1, PER2, PER3, CRY1, 
CRY2, BMAL1, CLOCK, and CKIε in a study on cancer-
ous and noncancerous tissues from 29 gastric cancer 
patients. They reported that PER2 was notably up-regu-
lated in cancer tissues compared with noncancerous tis-
sues. In addition, up-regulation of CRY1 expression was 
markedly associated with the advancement of clinical 
stages of gastric cancer. They suggested that disruption 
of circadian rhythms may be associated with the develop-
ment of gastric cancer [29].
Chronotherapy and cancer treatment
New advances in chronobiology and the discovery of the 
clock genes that are responsible for the generation and 
coordination of biological rhythms have led to the devel-
opment of chronotherapy [52]. It has also been shown 
that regulation of circadian rhythms to achieve robust 
circadian function can optimize treatment effects in can-
cer patients. Robust circadian function can be achieved 
through programmed exercise, light exposure, meal tim-
ing, sleep scheduling, and administration of drug usage 
with optimal circadian timing [53].
Cancer chronotherapy is emerging as a novel therapeutic 
strategy that suggests the scheduled usage of anti-cancer 
drugs based on optimal timing and according to the circa-
dian rhythms of anti-cancer action [52, 53]. Cancer chron-
otherapy suggests the optimal timing based on circadian 
changes in the tolerability and efficacy of anticancer medi-
cations [54, 55]. Li et al. [55] suggested that a mathemati-
cal determination of optimal timing through the analysis 
of the REV-ERBα and BMAL1 regulatory transcription 
loop could improve tolerability to chemotherapy. Positive 
effects of chronotherapy have been shown in gastrointesti-
nal cancer patients who were treated by chronomodulated 
chemotherapy. In addition, the application of chronother-
apy in the treatment of CRC resulted in 39%–50% 5-year 
survival [52]. Considering the circadian modulation of 
sensitivity to many therapeutic cytotoxic targets, Davidson 
et  al. [56] suggested that controlling meal times may 
increase the efficacy of cancer treatment. The authors also 
suggested that these optimal timings could be designed 
according to the coincident times of greatest tumor sen-
sitivity and lowest sensitivity of host tissue to damage. 
Chronotherapy provides opportunities not only for opti-
mizing cancer treatment but also for development of new 
anticancer or supportive agents [57].
Conclusions
The available literature indicates the importance of regu-
lar circadian rhythms for human health. However, dis-
ruption of circadian rhythms has been widely reported to 
put our health at risk. Circadian disruption due to irregu-
lar environmental cues, which are the results of indus-
trialization and our modern lifestyle, leads to various 
chronic diseases, including cancer. These findings suggest 
that organizing our lifestyle according to environmental 
cues and daily biological rhythms can be a preventive fac-
tor that opposes cancer. Scheduling different therapeutic 
processes, such as drug usage and chemotherapy, accord-
ing to circadian biological rhythms may also optimize 
the effects of cancer treatment. It is further suggested 
that because aberrant epigenetic modifications are an 
important hallmark of cancer cells, carcinogenic effects 
of circadian disruption may have an epigenetic basis. 
The epigenetic function of some circadian components/
genes have yet to be investigated, but the identification 
of underlying epigenetic mechanisms of circadian dis-
ruption in different carcinomas is worth further efforts. 
Additionally, identification of these epigenetic mecha-
nisms may open up a new avenue for the production of 
new pharmaceuticals that regulate circadian rhythms and 
prevent cancer development.
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